-->

Sacituzumab govitecan receives FDA approval for triple-negative breast cancer

August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA clearance for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic treatments, at least one of which was for metastatic illness.

Sacituzumab govitecan was granted accelerated approval in April 2020 for patients with mTNBC who had previously had at least two treatments for metastatic illness. The confirmatory trial for the speedy approval was the next step.

Efficacy and safety were assessed in 529 patients with unresectable locally advanced or mTNBC who had relapsed after at least two prior chemotherapies, one of which could have been in the neoadjuvant or adjuvant setting, if progression occurred within 12 months, in a multicenter, open-label, randomised trial (ASCENT; NCT02574455). On days 1 and 8 of a 21-day (n=267) cycle, patients were randomised (1:1) to receive sacituzumab govitecan, 10 mg/kg as an intravenous infusion, or a physician’s choice of single agent chemotherapy (n=262).

The primary effectiveness outcome was progression-free survival (PFS) in patients who did not have brain metastases at the start of the study, as determined by a blinded, independent, centralised review using RECIST 1.1 criteria. PFS for the entire cohort (with and without brain metastases) and overall survival were also included as effectiveness objectives (OS).

Patients receiving sacituzumab govitecan had a median PFS of 4.8 months (95 percent confidence interval: 4.1, 5.8) compared to 1.7 months (95 percent confidence interval: 1.5, 2.5) in those receiving chemotherapy (HR 0.43; 95 percent confidence interval: 0.35, 0.54; p0.0001). The median OS was 11.8 months (95 percent confidence interval: 10.5, 13.8) for men and 6.9 months (95 percent confidence interval: 5.9, 7.6) for women (HR 0.51; 95 percent confidence interval: 0.41, 0.62; p0.0001).

Nausea, neutropenia, diarrhoea, lethargy, alopecia, anaemia, vomiting, constipation, rash, decreased appetite, and abdominal discomfort are the most prevalent side events (incidence >25%) in patients taking sacituzumab govitecan.

Until disease progression or intolerable toxicity, the recommended sacituzumab govitecan dose is 10 mg/kg once weekly on days 1 and 8 of 21-day therapy cycles.

 

Reference : https://www.fda.gov/

Check details here.

Take second opinion on breast cancer treatment


Send Details

Susan Hau
Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • August 25th, 2021

The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma

Previous Post:
nxt-post

Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer

Next Post:
Tags:
, , , ,

Scan the code